SAN
DIEGO, April 21,
2015 /PRNewswire/ -- CorTechs Labs, the leading medical
software innovator providing solutions for quantitative brain
volume analysis is pleased to announce a partnership agreement with
Novartis Pharma AG, a global pharmaceutical
company. The companies will collaborate to
develop NeuroQuant's powerful brain volume quantification report
targeting the identification, measurement and tracking of brain
volume loss in multiple sclerosis patients.
The resulting report enables clinicians to automatically
conduct accurate and consistent measurements of the whole brain,
left and right thalami and the lateral ventricles out of 3D T1 MRI
images. The report is targeting the identification and tracking of
neurodegeneration in these sub-cortical structures. This
breakthrough solution, which is available both online and as an
installed software solution, provides neurologists and radiologists
with objective support of brain volume loss and its changes over
time and as compared to normative values.
"We're pleased to partner with Novartis to advance the clinical
care and assessment of multiple sclerosis worldwide," said
Guri Stark, CorTechs Labs'
CEO. "We believe this partnership will
empower clinicians with objective quantitative data, while
continuing NeuroQuant's growth momentum. This, in-turn furthers our
vision to establish NeuroQuant as the standard measurement solution
for all brain disorders, including Alzheimer's disease, epilepsy,
multiple sclerosis and traumatic brain injury."
About CorTechs Labs
CorTechs Labs develops and markets cutting-edge brain imaging
solutions used by neurologists and radiologists in hundreds of
clinics and research centers around the world.
CorTechs' flagship product, NeuroQuant®, is a breakthrough, 510(k)
cleared software medical device that makes quantitative analysis of
MRI images of the human brain a routine part of clinical
practice. As the first FDA cleared and CE marked medical
device capable of automatically detecting and quantifying atrophy
in the human brain, NeuroQuant® brings sophisticated,
accurate, and fully automated MRI post-processing capabilities to
the physician's desktop or mobile device. This provides
neurologists, radiologists, and clinical researchers with a
convenient and cost-effective means to quantify atrophy of brain
structures to help diagnose a variety of brain disorders, including
conditions such as Alzheimer's disease, epilepsy, multiple
sclerosis and traumatic brain injury. Please
visit www.cortechslabs.com or www.wholebrainatrophy.com for further
information.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cortechs-labs-announces-partnership-to-provide-comprehensive-solutions-for-quantifying-brain-volume-loss-in-multiple-sclerosis-300068877.html
SOURCE CorTechs Labs